Asset profile
onabotulinumtoxinA · Botox
Biologic (subtype unspecified)
Approvedregulatory verdict
Evidence outlook
Approved: Migraine
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Featured evidence outside covered markets:NCT06794866 · Forehead Lines · Phase 3 · completed · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
53 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 52 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| onabotulinumtoxinA (Botox): this drug | Approved | Biologic (subtype unspecified) | acetylcholine release, Acetylcholine Release Inhibitor | ||
| IncobotulinumtoxinA (Xeomin, PD Sialorrhea) | Phase 3 | Biologic (subtype unspecified) | acetylcholine release | ||
| Almotriptan (Axert) | Approved | Small molecule | — | ||
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | — | ||
| Atogepant (Qulipta) | Approved | Small molecule | — | ||
| Celecoxib (Elyxyb) | Approved | Small molecule | — | ||
| Diclofenac Potassium (Cambia) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | ||
| Dihydroergotamine (Atzumi) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Brekiya) | Approved | — | — | ||
| Dihydroergotamine Mesylate (D.H.E. 45) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Migranal) | Approved | — | — | ||
| Divalproex Sodium (Depakote ER) | Approved | — | GABAergic neurotransmission | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Eletriptan (Relpax) | Approved | Small molecule | — | ||
| Eptinezumab (Vyepti) | Approved | Monoclonal antibody | — | ||
| Erenumab (Aimovig) | Approved | Monoclonal antibody | — |
…and 38 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(27 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
November 2026 (1)
Phase 4Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Bladder …Not yet recruiting
Est. primary completion 2026-11 · NCT07387315 · CT.gov ↗
What to watch
December 2026 (1)
Early phase / not applicableIntraarticular Injection, Botox, Hyaluronic Acid, Knee OsteoarthritisRecruiting
Est. primary completion 2026-12-01 · NCT07666347 · CT.gov ↗
What to watch
2027 (18)
January 2027 (2)
February 2027 (3)
Phase 4Trigeminal NeuralgiaRecruiting
Est. primary completion 2027-02-01 · NCT06216886 · CT.gov ↗
What to watch
Early phase / not applicableOveractive Bladder (OAB), Botulinum Toxin Injection, Procedural Pain Relief, AnxietyNot yet recruiting
Est. primary completion 2027-02-20 · NCT07707791 · CT.gov ↗
What to watch
Early phase / not applicableUrgency Urinary IncontinenceActive not recruiting
Est. primary completion 2027-02-28 · NCT04731961 · CT.gov ↗
What to watch
March 2027 (3)
Phase 1Glabellar LinesRecruiting
Est. primary completion 2027-03 · NCT07756580 · CT.gov ↗
What to watch
Phase 4Neck Muscle IssueRecruiting
Est. primary completion 2027-03 · NCT06903975 · CT.gov ↗
What to watch
Phase 1Pelvic Floor DisordersRecruiting
Est. primary completion 2027-03-22 · NCT06796985 · CT.gov ↗
What to watch
May 2027 (2)
June 2027 (2)
August 2027 (2)
Phase 2Post-Mastectomy Neuropathic Pain SyndromeRecruiting
Est. primary completion 2027-08-30 · NCT06807164 · CT.gov ↗
What to watch
Phase 2/3Transfer Dysphagia, Oropharyngeal Dysphagia, Cricopharyngeus Muscle DysfunctionRecruiting
Est. primary completion 2027-08-31 · NCT04695600 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4MigraineNot yet recruiting
Est. primary completion 2027-10 · NCT07837570 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1WrinklesActive not recruiting
Est. primary completion 2027-12 · NCT02019004 · CT.gov ↗
What to watch
Phase 4Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia …Recruiting
Est. primary completion 2027-12-15 · NCT07220382 · CT.gov ↗
What to watch
Phase 2/3Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia …Recruiting
Est. primary completion 2027-12-31 · NCT06721520 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Phase 3Buerger Disease, Raynaud SyndromeNot yet recruiting
Est. primary completion 2028-02 · NCT05698979 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Overactive BladderRecruiting
Est. primary completion 2028-03-31 · NCT07648290 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1Spinal Cord InjuriesEnrolling by invitation
Est. primary completion 2028-04-30 · NCT06793683 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
2030 (3)
July 2030 (1)
Early phase / not applicableVocal TremorNot yet recruiting
Est. primary completion 2030-07 · NCT07577310 · CT.gov ↗
What to watch
August 2030 (1)
Early phase / not applicableStrabismic Deviation, StrabismusNot yet recruiting
Est. primary completion 2030-08-30 · NCT07180394 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1Fecal IncontinenceRecruiting
Est. primary completion 2030-09 · NCT06785844 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.